Non-invasive prenatal screening (Prendia)
Prendia involves a simple blood sample
When to take the test?
Prendia is indicated for pregnancies with a risk of chromosomal anomalies.
Groups at risk:
Pregnant women calculated to be at high risk (≥1/1000) at the first trimester screening (FTT), women whose ultrasound scans revealed anomalies or women with a specific medical history are deemed to belong to groups at risk.
Genetic predisposition
The risk of foetal chromosomal anomalies may be higher as a result of your own or your family’s medical history.
Mother’s age
The average age of women at the time of giving birth to their first child has increased steadily during recent decades and is currently around 31 (bfs.admin.ch).
The risk of trisomy
What is the Prendia Screening?
The Prendia non-invasive prenatal screening (NIPS) analyses foetal DNA in maternal blood obtained from a simple blood sample. It can be used to screen for chromosomal anomalies.
If this screening is positive, it will need to be confirmed by amniocentesis or choriocentesis. See factsheet Choriocentesis and amniocentesis.
Genetic counselling is available if you wish a more detailed explanation.
The Prendia non-invasive prenatal screening can be performed from week 10 (10 0/7) until the end of pregnancy.
The cost of the NIPS (Prendia START) is reimbursed under basic insurance coverage in Switzerland if an increased risk (≥1/1000) for trisomies 21, 13 or 18 was detected in the first trimester screening.
If you are interested in more comprehensive genetic screening, you can take the Prendia EXPERT screening at your own expense.
For more information : www.prendia.ch
Talk to your gynaecologist about Prendia.
Published by Medisupport Services SA, version 2022